← Shelf·Four-peptide combination stack (BPC-157 + TB-500 + GHK-Cu + KPV)·XXI.
KLOW.
A vendor-formulated combination of four research peptides — BPC-157 (a synthetic pentadecapeptide), TB-500 (a 17-residue fragment of thymosin β-4), GHK-Cu (the copper-tripeptide glycyl-histidyl-lysine), and KPV (the C-terminal α-MSH tripeptide lysine-proline-valine). Sold in a single lyophilized vial at approximately a 5-to-1-to-1-to-1 mass ratio favoring GHK-Cu (roughly 52 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 + 10 mg KPV per 80 mg vial, per the vendor's lot COAs). Each constituent has its own literature record; the combination itself is a marketing construct — essentially GLOW with KPV added — not a published research protocol.
The stack itself is not endogenous — it is a laboratory-manufactured combination. Where each ingredient comes from is covered in its own entry: BPC-157 as a synthetic fragment of Body Protection Compound (a stomach-lining protein), TB-500 as the active fragment of thymosin β-4, GHK-Cu as a copper complex of a tripeptide sequence found naturally in human plasma, and KPV as a C-terminal fragment of α-melanocyte-stimulating hormone.
Marketed as a quad regenerative stack — the sales pitch is that layering a fourth research peptide on top of the GLOW combination extends the profile into an additional research pathway. That framing has no published human trial data behind it in this specific four-way ratio. The consumer marketing routinely treats the sum as evidence-based when only the parts are individually documented, and treats each constituent's already-thin single-compound evidence as if it converted into support for the four-way combination. It does not.
Straight talk
Straight talk: there is not a single published human clinical trial of BPC-157 + TB-500 + GHK-Cu + KPV as a combination in the ratios sold. Not one. Every claim you will read about this stack is either (a) an extrapolation from single-compound preclinical work on one of the four constituents or (b) anecdotal community reporting. The individual constituents' evidence bases — each of them thin at the human-trial level — are best inspected in the individual entries. Combining four research compounds does not add evidence; it compounds the uncertainty four times over. Anyone selling this stack as a validated protocol is running years ahead of what any published research supports for the combination.
What the research studies
The literature, not a summary of it.
There is no literature on this specific four-peptide combination. What exists is the literature on each constituent, which is best consulted in the individual entries. For a combination-level search — expect essentially zero hits at the human-trial level — read the research yourself:
Recommended vendor · Amino Club
≥ 99% by HPLC on the current lot — ILS Laboratories (ISO/IEC 17025).
$64.99 during Fall Sale (was $99.99)
35% off applied automatically at checkout when you land through this link.